Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Gerlinger

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.
Frontiers in Oncology|October 5, 2020
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial DataKhurum Khan, Reyes Gonzalez-Exposito, David Cunningham, et al.
Genome Medicine|August 13, 2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton, James M Larkin, Marco Gerlinger, et al.
Nature Reviews. Cancer|September 16, 2017
Classifying the evolutionary and ecological features of neoplasmsCarlo C Maley, Athena Aktipis, Trevor A Graham, et al.
Genome Medicine|September 15, 2022
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapyFlorian A Büttner, Stefan Winter, Viktoria Stühler, et al.
Nature Genetics|February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingMarco Gerlinger, Stuart Horswell, James Larkin, et al.
Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Clinical Chemistry|August 29, 2018
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA SequencingSonia Mansukhani, Louise J Barber, Dimitrios Kleftogiannis, et al.
Microbiome|May 9, 2023
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancerJames L Alexander, Joram M Posma, Alasdair Scott, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.
Frontiers in Oncology|October 5, 2020
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial DataKhurum Khan, Reyes Gonzalez-Exposito, David Cunningham, et al.
Genome Medicine|August 13, 2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton, James M Larkin, Marco Gerlinger, et al.
Nature Reviews. Cancer|September 16, 2017
Classifying the evolutionary and ecological features of neoplasmsCarlo C Maley, Athena Aktipis, Trevor A Graham, et al.
Genome Medicine|September 15, 2022
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapyFlorian A Büttner, Stefan Winter, Viktoria Stühler, et al.
Nature Genetics|February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingMarco Gerlinger, Stuart Horswell, James Larkin, et al.
Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Clinical Chemistry|August 29, 2018
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA SequencingSonia Mansukhani, Louise J Barber, Dimitrios Kleftogiannis, et al.
Microbiome|May 9, 2023
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancerJames L Alexander, Joram M Posma, Alasdair Scott, et al.
Pageof 7